New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation…
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced…
AdvanCell Announces $18M MRFF Funding for Targeted Prostate Cancer Therapy AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of targeted cancer therapeutics, has received a significant boost from the Australian…
FDA Approves VYVGART Hytrulo Prefilled Syringe with ENHANZE for Self-Injection in gMG and CIDP In a major development for patients suffering from chronic neuromuscular autoimmune disorders, Halozyme Therapeutics, Inc. announced…
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs In a landmark moment for both Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and the broader scientific community, Paul Negulescu,…
Bruker Enhances IR Biotyper® for Hospital Hygiene with NGS Reflex Testing At the ESCMID Global 2025 conference, Bruker’s Microbiology and Infection Diagnostics division made a major announcement regarding the expansion…
Amneal Pharmaceuticals Commits $1.5 Million to Support Parkinson’s Disease Patients During Awareness Month In a powerful show of solidarity with the Parkinson’s community, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a global…
FDA Approves Opdivo and Yervoy Combo as First-Line Treatment for Advanced Liver Cancer In a significant advancement for liver cancer treatment, Bristol Myers Squibb (NYSE: BMY) has announced that the…
Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet…
Arcturus Therapeutics Secures FDA Fast Track Designation for ARCT-2304, a Next-Generation sa-mRNA Vaccine Targeting Pandemic Influenza A (H5N1) In a significant milestone for mRNA vaccine innovation, Arcturus Therapeutics Holdings Inc.…
Signios Biosciences Unveils Rebrand and Expands Vision as a Leading Multiomics and AI Bioinformatics Innovator in Precision Medicine In a bold step forward reflecting its evolution and expanded capabilities, Signios…
Avanzanite Bioscience Appoints Sotiris Botozis as Managing Director for Southern Europe Amid Strategic Expansion and Unprecedented Growth Avanzanite Bioscience BV, a rapidly growing player in the European life sciences and…